[National Institutes of Health (NIH)](https://www.nih.gov/)

April 10, 2026 (Estimated)

$50,000–$150,000 per award; up to $4.5M total program funding; ~9 awards expected

Supports further development and validation of emerging molecular and cellular analysis technologies to advance basic and clinical cancer research.

Forecasted opportunity; all dates and details are subject to change.

--- ## Description This opportunity from the National Cancer Institute (NCI) seeks applications for exploratory research projects focused on the advanced development and rigorous validation of new molecular or cellular analysis technologies relevant to cancer research. The goal is to accelerate or enhance research in cancer biology, early detection, screening, diagnosis, treatment, epidemiology, and to address cancer health disparities. Eligible projects must demonstrate that major feasibility gaps have been overcome with preliminary data, but require further development and validation to facilitate adoption by the research community. Technologies should focus on improving molecular and/or cellular characterizations of cancer and may have broad research applicability. Projects that primarily apply existing technologies to new biological or clinical questions (without technological innovation) are not appropriate for this solicitation. This funding opportunity is part of the NCI Innovative Molecular Analysis Technologies (IMAT) Program. --- ## Due Dates - Estimated application due date: April 10, 2026 *All dates are projected based on the annual cycle; check the program page for updates.* --- ## Funding Amount - Expected award range: $50,000–$150,000 per project - Estimated total program funding: $4,500,000 - Expected number of awards: Approximately 9 No cost sharing or matching is required. --- ## Eligibility Eligible applicants include: - State, county, city, township, and special district governments - Independent school districts - Public and state-controlled institutions of higher education - Native American tribal governments (federally recognized and other) - Public housing authorities/Indian housing authorities - Nonprofits (with or without 501(c)(3) status) - Private institutions of higher education - For-profit organizations (including small businesses) - U.S. territories and possessions - Faith-based or community-based organizations - Regional organizations - Eligible agencies of the federal government - Non-domestic (non-U.S.) entities (foreign institutions) --- ## Application Process - Review the full [opportunity listing on Grants.gov](https://www.grants.gov/search-results-detail/360534) for updates and application instructions. - Prepare an R33 application with robust preliminary data showing feasibility and a clear plan for further development and validation. - Submit all required materials by the listed deadline through the Grants.gov portal. --- ## Additional Information - Clinical trials are not allowed under this opportunity. - Technologies must be innovative and focused on molecular and/or cellular analysis of cancer. - Projects applying existing technologies to new targets without technical innovation will not be reviewed. --- ## External Links - [NIH Main Website](https://www.nih.gov/) - [Grants.gov Opportunity Listing](https://www.grants.gov/search-results-detail/360534) - [NCI Innovative Molecular Analysis Technologies (IMAT) Program](https://www.cancer.gov/research/resources/technology/innovative-molecular-analysis) --- ## Contact Information | Name | Email | Phone | |-------------------|---------------------------------------|---------------| | Kelly Crotty, Ph.D.| [Kelly.crotty@nih.gov](mailto:Kelly.crotty@nih.gov) | 240-255-0917 |

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Sign in to see full grant listing